IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release

• Main Authors: John S. Schardt (Author), Even Walseng (Author), Kim Le (Author), Chunning Yang (Author), Pooja Shah (Author), Ying Fu (Author), Kausar Alam (Author), Cathryn R. Kelton (Author), Yu Gu (Author), Fengying Huang (Author), Jia Lin (Author), Wenhai Liu (Author), Andrew Dippel (Author), Hanzhi Zhang (Author), Kathy Mulgrew (Author), Stacy Pryts (Author), Vijaykumar Chennupati (Author), Hung-Chang Chen (Author), Jessica Denham (Author), Xiaoru Chen (Author), Pallab Pradhan (Author), Yuling Wu (Author), Colin Hardman (Author), Chihao Zhao (Author), Michael Kierny (Author), Yang Song (Author), Simon J. Dovedi (Author), Saso Cemerski (Author), Yariv Mazor (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

T cell engagers (TCEs) are becoming an integral class of biological therapeutic owing to their highly potent ability to eradicate cancer cells. Nevertheless, the widespread utility of classical CD3-targeted TCEs has been limited by narrow therapeutic index (TI) linked to systemic CD4+ T cell activat...